Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

The results of the Explorer7 trial showed that concizumab – an anti-tissue factor pathway inhibitor (TFPI) antibody – reduced the number of treated bleeds in patients by 86% when given as a ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...